Elucid, a medical technology company focused on AI-powered cardiovascular imaging, has raised $55 million in an oversubscribed Series D financing round. The new capital brings the company's total funding to approximately $185 million and includes participation from a large medtech company that becomes its fourth publicly traded strategic investor. The investment signals growing confidence in Elucid's approach to non-invasive cardiovascular diagnostics.
Funding Details and Strategic Expansion
The round includes new and existing investors such as IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital. Proceeds will support the commercial expansion of Elucid's clinical platform, including FFR-CT and Plaque-IQ. The funding will also advance the company's artificial intelligence research and landmark clinical studies.
Investor Validation and Market Confidence
The addition of the new medtech investor as Elucid's fourth publicly traded strategic partner underscores the industry's confidence in its technology. The oversubscribed nature of the Series D round reflects strong demand from both new and existing backers. This strategic alignment is expected to accelerate Elucid's commercial reach and integration with established medical device ecosystems.
AI-Powered Diagnostic Platform
Elucid's technology converts routine CT angiography into detailed quantitative insights based on plaque biology, vessel anatomy, and FFR physiology. These insights are designed to help clinicians stratify at-risk patients and personalize treatment strategies for atherosclerotic cardiovascular disease, the leading cause of death worldwide. The platform represents a shift toward precision medicine in cardiovascular care similar to advancements seen in oncology.
Regulatory Progress and Product Readiness
Elucid is preparing for a full commercial launch following its 510(k) submission for the BioIntegrated FFR-CT product, which is currently under FDA review. The product is designed to provide high accuracy and reproducibility compared with invasive fractional flow reserve measurements. Together with the FDA-cleared Plaque-IQ software, the FFR-CT offering will include a novel user interface and reporting workflow to form a comprehensive clinical decision platform.
Unique Plaque Quantification Capability
Plaque-IQ is the only FDA-cleared non-invasive method able to quantify the highest-risk plaque type and plaque composition in coronary and carotid arteries. Its accuracy has been validated against histopathology, the gold standard for tissue-based diagnosis. This capability is central to Elucid's goal of revealing the biological drivers of heart attacks and strokes before they occur.
Executive Perspective on Precision Cardiovascular Care
Kelly Huang, PhD, chief executive officer of Elucid, likened the company's approach to oncology's transition away from population-based, one-size treatment. He noted that Elucid is applying artificial intelligence to integrate anatomy, biology, and physiology for personalized coronary artery disease management. Physician feedback indicating that the current platform can lead to better care decisions reinforces the company's mission to predict and personalize prevention.
Future Growth and Clinical Impact
With this latest financing, Elucid aims to deepen collaborations with leading medical technology companies and broaden access to its diagnostic tools. The company's ongoing clinical studies are expected to generate further evidence supporting the clinical and economic value of its platform. These efforts position Elucid to shape the next generation of cardiovascular risk assessment and treatment planning.
The $55 million Series D round marks a significant milestone for Elucid as it advances commercial readiness and expands its strategic investor base. With a clinically validated platform and regulatory momentum, the company is well positioned to address the global burden of cardiovascular disease. Elucid's continued investment in AI-driven diagnostics may help shift cardiovascular care toward earlier, more personalized intervention.